Recent studies have estimated the prevalence of hereditary hemochromatosis to be 3 to 8 per 1000.
Early detection and treatment can prevent disease manifestations and normalize life expectancy.
We used decision analysis techniques to determine whether screening the population at large for hereditary hemochromatosis would be cost-effective.
We constructed a model to compare the cost and outcome of a strategy of performing screening transferrin saturation tests on cohorts of 30-year old men with that of awaiting symptomatic disease.
Baseline estimates of disease prevalence and complication rates were based on the published literature.
Costs of treatment were estimated based on prevailing local costs.
Mots-clés Pascal : Métabolisme pathologie, Economie santé, Maladie héréditaire, Dépistage, Homme, Hémochromatose, Coût
Mots-clés Pascal anglais : Metabolic diseases, Health economy, Genetic disease, Medical screening, Human, Hemochromatosis, Costs
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0431412
Code Inist : 002B22E03. Création : 199406.